Vogt-Koyanagi-Harada Syndrome: A COVID Sequela?

Hispanic/Latinx, and 2% American Indian and Alaskan Native).Respondents experienced a mean (standard deviation [SD]) journey time of 49.0 (92.8) months from symptom onset to NMOSD diagnosis; most delays occurred after seeking care.White respondents had shorter total journeys compared with POC (27.1 [55.4] vs 72.3 [118.2]months).Common (10% of respondents) reported reasons for delayed diagnosis were difficulty navigating insurance coverage (24%) and accessing specialty care (12%), lack of provider knowledge (12%), race/ ethnicity (12%), and income (10%).Mean (SD) number of HCPs seen for all respondents was 4.8 (5.1).POC and women reported HCPs dismissed their symptoms as emotional problems, comorbidities, or drug-seeking behaviors.Most (74%) survey respondents reported their journey was "stressful" or "very stressful" (very stressful: POC, 57%; White, 43%).Patients and HCPs identified solutions to overcome barriers that included increasing knowledge about NMOSD, accessing health care appointments, and accessible medical records for HCPs. Conclusions ResultsA 27-year-old man with no past medical history presented with a twoweek history of intermittent unilateral headache, bilateral eye pain with photophobia, and phonophobia, followed by tinnitus and blurry vision, which ultimately progressed to total bilateral vision loss.VDRL, FTA, QuantiFERON gold, flow cytometry, cytology, and cultures were all negative, except for moderate pleocytosis with lymphocytic